Cavidi launches novel platform technology – Exazym®
To showcase of the potential utility of Exazym®, we have demonstrated its ability to measure human anti-spike IgG antibodies, a biomarker for Sars-Cov-2 in serum samples. With its significantly enhanced sensitivity and simplicity, Exazym® can pave the way toward the discovery of new biomarkers for early disease diagnosis and improved health outcomes.
Nordic Collaboration for SARS-CoV-2 virology and serology testing
Nordic virus monitoring and diagnostics’ companies Cavidi and BioPorto have initiated a joint collaboration to utilize Cavidi’s ZIVAä system to enable antigen detection of an existing SARS CoV-2 infection as well as antibody detection of a past infection. The tests will run on ZIVA, a fully automated instrument for distributed, front line rapid testing scale-up.
Olof Larsson joins Cavidi as R&D Director
Olof has an academic background with a Ph.D. Pharmacology and a Postdoc Electrophysiology at Karolinska Institute. He brings a long experience heading up research teams at international companies like Eli Lilly Inc. (US) and Astra Zeneca ranging a number of clinical areas such neurodegenerative diseases.
COVID-19 and HIV how we can learn from pandemics
In times of uncertainty and crisis, clear information saves lives. This is as true on a national level as it is in the clinic.
Walter Campos MBA, MSc, PhD Virology has been promoted to Commercial Director, Africa
Walter Campos MBA, MSc, PhD Virology has been promoted to Commercial Director, Africa. Walter has been working with Cavidi since 2012 and most recently served as Operations Director for Africa. In his expanded role Walter will be responsible for Cavidi commercial and distribution management in Africa.
Cavidi secures ALMI grant to expand presence in US market
The gene therapy market in the United States is growing rapidly, fueled in part by new gene editing technologies such as CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats). Scaling gene therapy will require a number of new technologies for both researchers and clinicians.
Cavidi finalists in Uppsala Innovation Award 2018
"It was an honour to be nominated especially when one sees the variety of the companies involved and the number of industries" said John Reisky de Dubnic, CEO of Cavidi. "We represent life science which is an important sector in Uppsala but the other nominees were from completely different industries.
Innovation success is mission possible at Cavidi
Cavidi’s innovation is aimed at closing the gap betweenr the market need for Viral Load and current capabilities for decentralised testing. Our innovation is delivered in three parts: https://www.mynewsdesk.
Cavidi an HIV diagnostics industry leader sets sights on virus containment
The Human Immunodeficiency Virus (HIV) has puzzled scientist around the world for decades. Since its discovery in the early 80's the virus has caused one of the worst pandemics the world has seen in modern times.
EIB Venture Debt launch event March 22, 2018, Luxembourg
VP of European Investment Bank Ambroise FAYOLLE presents award for Innovation in Infectious Diseases to John Reisky de Debnic, CEO Cavidi. Cavidi was the first to receive funding with debt placement of €10,000,000 loan from the EIB Venture Debt product.